Abstract
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Full Text
What is claimed is:
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Timeline
Filed
03/05/2026Published
07/09/2026Granted
Not AvailableIPC Codes(5)
A61K 31/519:ortho- or peri-condensed with heterocyclic rings
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 9/06:Ointments; Bases therefor (apparatus for making A61J 3/04)